Separation and characterization of clindamycin phosphate and related impurities in injection by liquid chromatography/electrospray ionization mass spectrometry

A simple high‐performance liquid chromatography/electrospray ionization tandem mass spectrometric (HPLC/ESI‐MS/MS) method has been developed for the rapid identification of clindamycin phosphate and its degradation products or related impurities in clindamycin phosphate injection. Detection was performed by quadrupole time‐of‐flight mass spectrometry (Q‐TOFMS) via an ESI source in positive mode. Clindamycin phosphate and its related substances lincomycin, 7‐epilincomycin‐2‐phosphate, lincomycin‐2‐phosphate, clindamycin B, clindamycin B‐2‐phosphate, and clindamycin were identified simultaneously by HPLC/ESI‐MS/MS results. Based on the MS/MS spectra of their quasi‐molecular ions, the fragmentation pathways of clindamycin phosphate and its related substances were compared and proposed, which are specific and useful for the identification of the lincosamide antibiotics and related impurities. The method was rapid, sensitive and specific and can be used to identify clindamycin phosphate and its related impurities in clindamycin phosphate injection without control compounds. Copyright © 2009 John Wiley & Sons, Ltd.     

高效液相色谱-电喷雾串联质谱法测定蜂蜜中的林可胺类抗生素残留

建立了蜂蜜中林可胺类抗生素林可霉素和氯林可霉素的高效液相色谱-电喷雾串联质谱(HPLC/ESI-MS/MS)检测方法。样品经固相萃取提取净化、反相液相色谱分离后进行质谱分析,在选择反应监测模式(SRM) 下进行特征母-子离子对信号采集。根据保留时间、母离子和两个特征子离子信息进行定性分析,以共同的基峰离子m/z 126进行定量。两种抗生素的检测限(S/N=3) 为 0.1 μg/kg,定量限为 0.5 μg/kg,在1.0～200 μg/L时峰强度与质量浓度的线性关系良好(r2>0.996)。在1.0,5.0,20.0 μg/kg 3个添加水平,两种抗生素的平均回收率范围为80%～110%,日内测定结果的相对标准偏差小于8%,日间测定结果的相对标准偏差小于15%。结果表明,该法简单、灵敏,特异性强,适用于蜂蜜中林可胺类抗生素残留的分析确证。     

Synthesis,characterization and control of eight process-related and two genotoxic fingolimod impurities by a validated RP-UPLC method

An HPLC method has been described in the European Pharmacopoeia and United States Pharmacopeia for the determination of nine organic impurities (imp A–I) in fingolimod hydrochloride, a synthetic sphingosine-1-phosphate receptor modulator. The manufacturing process of fingolimod hydrochloride consists of multistep chemical synthesis wherein controls of precursors, intermediates and process steps should be performed to assure the final quality of the drug substance. We synthesized and isolated eight process-related impurities (FINI imp A–H) of fingolimod, which were different from the pharmacopoeial impurities. One unknown process-related impurity was found as a key intermediate (FINI) and was identified by LC–MS. Characterization of all of the impurities were done using spectroscopic techniques (¹H and ¹³C NMR, FTIR, MS), and the mechanistic pathways to the formation of these impurities were also discussed. Two of these impurities were evaluated as potential genotoxic impurities owing to their alerting structures and alkylating properties (alkyl sulfonates and alkyl halides, class 3, ICH M7). We also developed and validated an RP-UPLC method in line with ICH Q2 guidelines for control these impurities (FINI imp A–H) and to assure the pharmacopoeial quality drug substance.     

Determination of minor impurities in temafloxacin hydrochloride by high-performance liquid chromatography

Minor impurities in the antibacterial agent temafloxacin hydrochloride were determined using high-performance liquid chromatography. Manufacturing impurities and degradation products were separated using a reversed-phase system with gradient elution. Detector response was linear for the individual impurities to approximately 50 micrograms/ml which represents 2.5% of the drug concentration. The procedure provides quantitation of impurities to approximately the 0.05% level with precision (relative standard deviations) of 4.7% to 29% in typical bulk drug lots. A variety of reversed-phase columns were evaluated for the assay method with optimum resolution achieved using a 5-microns Nucleosil C18 packing.     

非法冰毒晶体中有机杂质的气相色谱-质谱分析

建立了一种适用于分析冰毒杂质的方法,并分析其形成原因。将冰毒样品溶于1 mL 0.1 mol/L pH7.0的磷酸盐缓冲液(4份缓冲液1份10%Na2CO3),杂质用0.5 mL乙酸乙酯萃取。结果共有8种物质被检出。N-甲酰甲基安非他明、N-乙酰甲基安非他明在样品中出现,说明此批冰毒由苯丙酮(phenyl-2-propanone,P-2-P)经Leuckart法合成。N-乙基甲基安非他明的检出,则说明用于合成此批冰毒的P-2-P由苯甲醛和硝基乙烷合成。从实验结果看,该法可以满足冰毒杂质分析的需要,为分析冰毒杂质成分的成因、判断冰毒样品的合成路径提供重要信息。     

Validation of a high-performance liquid chromatographic method for the simultaneous determination of tramadol and its impurities in oral drops as a pharmaceutical formulation

The novel, rapid high performance liquid chromatographic method for the determination of tramadol hydrochloride and its three impurities was developed and validated. The method can simultaneously assay potassium sorbate, used as preservative, and saccharin sodium, used as sweetener in tramadol pharmaceutical formulation. The separation was carried out on a C(18) XTerra (150 mm x 4.6 mm, 5 mm) column using acetonitrile-0.015 M Na(2)HPO(4) buffer (2:8, v/v) as mobile phase (pH value 3.0 was adjusted with orthophosphoric acid) at a flow rate 1.0 ml min(-1), temperature of the column 20 degrees C and UV detection at 218 nm. The method was found to be linear (r > 0.999) in the range of 0.05-0.8 mg ml(-1) for tramadol hydrochloride, 0.1-1.2 mg ml(-1) for impurities B and C and for impurity A (r > 0.995) in the range 0.15-2.4 mg ml(-1). The low RSD values indicate good precision and high recovery values indicate excellent accuracy of the HPLC method. Developed method was successfully applied to the determination of tramadol hydrochloride, its investigated impurities and potassium sorbate in commercial formulation. The recovery of tramadol hydrochloride was 98.25% and RSD was 1.80%. The method is rapid and sensitive enough to be used to analyse Trodon oral drops.     

莫西沙星及其杂质的合成研究进展

莫西沙星是第四代喹诺酮类抗菌药物,具有抗菌谱广、抗菌活性强、低毒等特点,因此在临床上得到了广泛的应用。莫西沙星在生产、储存过程中容易产生杂质,为了确保临床用药安全有效,莫西沙星的杂质需要进行控制。本文主要对莫西沙星及其杂质的合成研究进展进行综述。     

Facilitated column selection in pharmaceutical analyses using a simple column classification system

In this paper, the performance of a previously developed classification system applied to pharmaceutical chromatographic analyses, is investigated. The separation of seven different drug substances from their respective impurities was studied. The chromatographic procedure for acetylsalicylic acid, clindamycin hydrochloride, buflomedil hydrochloride, chloramphenicol sodium succinate, nimesulide and phenoxymethylpenicillin was performed according to the corresponding European Pharmacopoeia (Ph. Eur.) monograph. The separation of dihydrostreptomycin sulphate was performed according to the literature. It is shown that the column ranking system is a helpful tool in the selection of a suitable column in these analyses.     

Investigation of enantiomeric separation of basic drugs by capillary electrophoresis using clindamycin phosphate as a novel chiral selector

A wide number of chiral selectors have been employed in CE and among them macrocyclic antibiotics exhibited excellent enantioselective properties toward plenteous racemic drugs. Different from macrocyclic antibiotics, the use of lincomycin antibiotics as chiral selectors has not been reported previously. In this study clindamycin phosphate belonging to the group of lincomycin antibiotics is first used as a novel chiral selector for the enantiomeric separations of several racemic basic drugs, which possess high separability, consisting of nefopam, citalopram, tryptophan, chlorphenamine and propranolol. Other basic drugs giving partial enantioseparation include tryptophan methyl ester, metoprolol and atenolol. Clindamycin phosphate possesses advantages such as high solubility and low viscosity in the water and very weak UV absorption. In the course of this work we observed that both migration time and enantioseparation were influenced by several parameters such as pH of the BGE, clindamycin concentration, capillary temperature, applied voltage and organic modifier. The optimum pH that was in the neutral or weak basic region but varied among drugs, a low capillary temperature and a clindamycin concentration of 60 or 80 mM are recommended as the optimum conditions for chiral separation of these drugs. Moreover, comparison of the influences of the studied parameters was further investigated by means of Statistical Product and Service Solutions in this paper.     

Identification and characterization of the process‐related impurities in fasudil hydrochloride by hyphenated techniques using a quality by design approach

Following the underlying principles of quality by design mentioned in the ICH Q8 guidance, systematic approaches for the control of process‐related impurities have been taken in the manufacturing process of fasudil hydrochloride, a potent Rho‐kinase inhibitor and vasodilator. Three related impurities were found in fasudil hydrochloride lab samples by a newly developed RP‐HPLC with volatile mobile phase gradient elution and UV detection method. The elemental compositions of the impurities were determined by positive ESI high‐resolution TOF‐MS analysis of their [M + H]⁺ ions and their structures were identified through the elucidation of the product mass spectra obtained by a triple quadrupole mass spectrometer. The key impurity was further verified through synthesis and organic spectroscopy including NMR and IR spectroscopy. The origins of these impurities were located and the effective approaches to eliminate them were proposed based on the redesign of the synthetic conditions. The results obtained are important for quality control in the manufacture of fasudil hydrochloride bulk drug substance and injection.     

Synthesis of Valganciclovir Hydrochloride Congeners

Valganciclovir hydrochloride (1) is used for the treatment of cytomegalovirus (CMV) retinitis in patients with weakened immune systems. Valganciclovir hydrochloride is a hydrochloride salt of L-valyl ester of ganciclovir (2) that exists as a mixture of two diastereomers. According to the U.S. Food and Drug Administration specifications, the diastereomeric ratio of valganciclovir hydrochloride 1 should be maintained in the range 55:45 to 45:55. According to the U.S. Food and Drug Administration specifications, the diastereomeric ratio of valganciclovir hydrochloride 1 should be maintained in the range 55:45 to 45:55. During the process development of valganciclovir hydrochloride, six related substances (impurities) were observed along with the final active pharmaceutical ingredient. Among these six impurities, ganciclovir (2) and guanine (3) are the key starting materials and degraded impurities of ganciclovir, respectively. The remaining four impurities were identified as isovalganciclovir hydrochloride (4), methoxymethylguanine (5), O-acetoxy ganciclovir (6), and isovalarylganciclovir (7). The present work describes the synthesis and characterization of these four impurities.     

On-Line Concentration Methods for Analysis of Fat-Soluble Vitamins by MEKC

A fast, selective and sensitive reversed phase liquid chromatographic method employing a C-18 column has been developed and validated for simultaneous analysis of four impurities of duloxetine hydrochloride, an antidepressant drug, viz., (S)-N,N-dimethyl-3-hydroxy-(2-thienyl)-propanamine, phenolic impurity, 1-napthol and duloxetine succinamide. Good separations were achieved by a gradient elution with mobile phase consisting of a mixture of phosphate buffer 14 mM containing 0.1% of sodium octanesulfonate, pH 3.0, at a flow rate of 0.8 mL min^?1. The detection was at 220 nm. The method was validated for precision, linearity and accuracy. Finally, the developed method was used to quantify the impurities during stability sample analysis of duloxetine hydrochloride drug products.     

Spectrophotometric and Indirect Determination of Lincomycin by Atomic Absorption Spectroscopy (AAS)

Abstract

The reaction of lincomycin with cupric ions in alkaline medium was taken as a basis for the colorimetric and indirect atomic absorption spectrometric (AAS) determination of lincomycin hydrochloride.

The AAS procedure was based on the extraction of copper-lincomycin complex at pH 11, into n-butanol. The copper content in this extract was determined by AAS. The response was linear for up to 30 μg ml^?1 of lincomycin. The method is accurate, sensitive and simple.

The proposed methods were applied to pharmaceutical preparations with fine accuracy.     

A systematic study of determination and validation of finasteride impurities using liquid chromatography

Pharmaceutical use of finasteride (Dilaprost®) has been well documents in the peer-reviewed literature; however, the presence of trace amounts of related substances (impurities) in finasteride may influence the tharapeutic efficacy and safely. Due to limited information available, the objective of this study was to develop a quantification method for the three impurities of finasteride using high performance liquid chromatography (HPLC) with an ultraviolet (UV) detector. The compounds (impurities) of finasteride that are registered with the European Pharmacopeia, which we sought to validate are: -N-(1,1-dimethylethyl)-3-oxo-4-aza-5α-androstane-17β-carboxamide (impurity A), methyl 3-oxo-4-aza-5α-androst-1-ene-17β-carboxylate (impurity B), and -N-(1,1-dimehylethyl)-3-oxo-4-azaandrosta-1,5-diene-17β-carboxamide (impurity C). Analyses were performed using a Nova Pac C₁₈ column for HPLC with isocratic elution. Detection was carried out at 210 nm, the concentration of the three impurities was in the range was 1.5–4.5 μg mL⁻¹ at ambient temperature with a mobile phase of water + acetonitrile + tetrahydrofuran (80:10:10, v/v/v) and the flow rate was 2.0 mL min⁻¹. The recoveries were: 101.35 ± 0.62% (impurity A), 101.60 ± 2.66% (impurity B) and 101.97 ± 2.05% (impurity C). Validation of the method yielded fairly good results as it relates to the precision and accuracy. It is, therefore, concluded that the method would be suitable for not only the separation and determination of processed impurities to monitor the reactions, but also for the quality assurance of finasteride and its related substances.     

Validatibility of a capillary isoelectric focusing method for impurity quantitation

A strategy is presented for examining the validatability of a capillary isoelectric focusing (cIEF) method, intended for quantitation of product-related impurities in a protein drug substance, according to guidelines published by the International Conference on Harmonization (ICH). The results of this study demonstrate the suitability of cIEF as an analytical method for the quantitation of two product-related impurities in a protein drug substance: a monodeamidated degradation product and an aggregated form of the parent molecule. A range of impurity levels was generated by spiking the isolated impurity species, into a representative production lot of the drug substance. Six impurity spike levels (0.5-12% impurity for deamidated species and 0.5-8% impurity for aggregated species) were analyzed in triplicate. Measurement of impurity peak area percent in the spiked samples provided the data for computing specificity, accuracy, precision, linearity and limit of quantitation (LOQ) for the impurities. Accuracy, defined as the agreement of peak area percent for impurity species with the theoretical impurity percentage from the spike ratio, was 85-96% for the deamidated species and 73-97% for the aggregated species. A linear relationship was found between the measured area percent and the theoretical percent impurity for both impurity species (coefficient of determination, r2=0.9994 for deamidated species and =0.9827 for aggregated species). Precision (repeatability) studies demonstrated a low relative standard deviation (RSD) value (<6%) at all spike levels for both impurity species. Intermediate precision and reproducibility were evaluated by simulating many of the multivariable testing conditions expected during the life cycle of an analytical method, such as multiple equipment and laboratories. Repeated analyses of the drug substance under these varied conditions, yielded RSD values of <20%, for both impurity species. The LOQ, defined as the lowest impurity level where both accuracy and precision were achieved, was assigned at the 0.5% impurity level for both impurity species. This work illustrates a successful strategy in applying the ICH validation guidelines for impurity analytical methods to a cIEF method. Moreover, the data demonstrate the ability of cIEF to be used reliably as an analytical method for impurity quantitation.     

UHPLC Study on the Degradation Profiles of Olopatadine Hydrochloride in Eye Drops Subjected to Heat and Filtration Methods of Sterilisation

A validated ultra-high performance liquid chromatography (UHPLC) method has been proposed, validated and used for the determination of olopatadine hydrochloride degradation products in olopatadine 1 mg mL^?1 eye drops solution under the influence of two different sterilisation methods, heating and filtration, with good precision and accuracy. We found that the heat sterilization method yields a higher content of olopatadine hydrochloride degradation products in eye drops compared to unsterilized drug product or drug product sterilized by filtration, except for α-hydroxy olopatadine impurity, which remains stable with time and applied sterilization method. Contents of olopatadine related compound B shows a higher increase (from <0.005 to 0.044 %) when sterilised by heating than when subjected to aging and sterilization by filtration (increase up to 0.011 %). Similarly, total amount of all impurities is also increased from 0.13 to 0.49 % when the drug product is sterilised by heating instead of filtration (up to 0.39 %). Content of olopatadine related compound B and of all impurities is increased by aging, probably through thermal and oxidative degradation. Forced degradation studies were correlated with the sterilisation study and possible degradation pathways were identified. Olopatadine shows strong degradation under oxidative and moderate degradation under photolytic environment, with the olopatadine related compound B as the main degradation product. Sterilization of eye drops solution by filtration is recommended.     

Quantitative impurity profiling by principal component analysis of high-performance liquid chromatography-diode array detection data

Related organic impurities generally have approximately similar molar absorption coefficients (epsilon) due to their structural similarities. On the assumption that all peaks in an impurity profiling chromatogram have approximately the same maximum molar absorption coefficients (epsilon(max)) and the chromatogram contains one major peak and several much smaller ones, all of which are completely separated, integration of the summed score vectors from the principal component analysis (PCA) decomposition of high-performance liquid chromatography-diode array detection (HPLC-DAD) data will give areas that are quantitatively proportional to the actual content of the compounds. Due to the sequential nature of PCA, the first principal component (PC) will primarily be related to the main compound and all peaks showing a similar spectrum, while the second PC will be related to the impurities with a spectrum different from the main peak. Summing the two score vectors thus makes it possible to take account of different spectra in the score chromatogram, which make the method proposed give better quantitative estimates of the impurities than any single wavelength chromatogram. Multivariate curve resolution alternating least squares (MCR-ALS) is used for comparison. The results are presented for two examples of simulated HPLC-DAD data as well as for three examples of real HPLC-DAD data from impurity profiling. The results show that integration of the score chromatograms can handle differences in the unknown epsilon(max) of the peaks and take account of the different spectra of the impurity peaks, giving quantitative estimates of the content of the impurities that closely correspond to the reference values. The results obtained are also better than integration with the best possible separate wavelength. The method could be a straightforward approach to impurity profiling in order to obtain a good estimate of the content or relative response factors of small chromatographic impurity peaks without knowledge of their molar absorption coefficients and without any precalibration.     

Conductivity,impurity profile,and cytotoxicity of solvent‐extracted polyaniline

Understanding the correlation between the preparation, purification, impurity leaching, and cytotoxicity of polyaniline is crucial for the application of this conducting polymer in biomedicine. Polyaniline hydrochloride was purified in a Soxhlet extractor by using six different solvents: methanol, 1,2‐dichloroethane, acetone, ethyl acetate, hexane, or 0.2 M aqueous hydrochloric acid. The chromatographic analyses of impurities leached out of the polymer into the solvents confirmed differences in impurity profiles, which depended on the polarity of the extraction solvent. Compared with the original polymer, the conductivity of purified polyanilines increased in dependence on the amount and type of extracted impurities. The cytotoxicity of purified samples determined on the mouse embryonic fibroblast cell line NIH/3T3 using MTT assay improved as well. Methanol and 0.2 M hydrochloric acid were the most efficient solvents capable of extracting low‐molecular‐weight impurities, and thus reducing polyaniline cytotoxicity. The absence of cytotoxicity was observed at an extract concentration of 10%. Extraction with suitable solvents can, therefore, be a possible way of obtaining cyto‐compatible polyaniline with sufficient conductivity. Copyright © 2015 John Wiley & Sons, Ltd.     

Analysis of human parathyroid hormone (1-84) products. Separation of a major impurity in synthetic products by ion-pairing reversed-phase high-performance liquid chromatography

Human parathyroid hormone (1-84) is a naturally occurring polypeptide that acts as the major regulator of calcium ion homeostasis. It can be efficiently produced through both synthetic and biosynthetic routes and, as such, highly selective analytical methods are required for the detection of a wide range of impurities. Herein we report on the development of an ion-pairing reversed-phase HPLC method for the analysis of human parathyroid hormone and the separation of impurities including a major, unidentified impurity detected in synthetic preparations. This impurity could not be resolved using trifluoroacetic acid-based methods generally used for monitoring purity levels in commercial products. Separation conditions consisted of a gradient elution of 0.155 M sodium chloride containing 0.037 M sodium pentanesulfonate, pH 5.6, as mobile phase A and acetonitrile as mobile phase B. Separations were carried out on an octadecylsilyl silica column maintained at 50 degrees C. Both column temperature and pH of mobile phase A significantly affected the separation of the major impurity. The major impurity eluted after the main human parathyroid peak and was detected in the two commercial synthetic products analyzed. Several minor impurities eluting before and after the main peak were also detected. Purity levels measured by the developed HPLC method (method C) were similar to those previously measured by capillary electrophoresis. Analysis of purified recombinant human parathyroid hormone did not show the presence of this impurity. This method offers a significant advantage for the purity assessment of human parathyroid hormone.     

Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry

Three unknown impurities in an amodiaquine bulk drug sample were detected by reversed-phase high-performance liquid chromatography with ultraviolet detection (HPLC/UV). A liquid chromatography/tandem mass spectrometry (LC/MS(n)) method is described for the investigation of these impurities. Mass spectral data were acquired on an LCQ ion trap mass analyzer equipped with an electrospray ionization (ESI) source operated in positive ion mode. The fragmentation behavior of amodiaquine and its impurities has been studied. Based on the mass spectral data and the specifics of the synthetic route, the possible structures of these impurities were elucidated as 4-[(5-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol (impurity I), 4-[(7-chloroquinolin-4-yl)-amino]phenol (impurity II) and 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-N(1)-oxy]phenol (impurity III). The structures were confirmed by their independent synthesis and NMR spectral assignment.